On Monday, September 19, 2022, Texas Retina Associates’ or Worse Vision?”, delivered a webinar titled, “Does Treatment Selection Matter in Patients with Diabetic Macular Edema and 20/50
Dr. Abbey discussed the increasing prevalence of diabetic macular edema (DME) and the high prevalence of 20/50, or worse, vision in DME patients. He reviewed data on earlier treatment with an anti-VEGF agent for this group of patients as well as evidence supporting the first-line use of EYLEA, including a patient case. In addition, he reviewed the safety information for EYLEA and presented the Protocol T study about anti-VEGF treatment in patients with DME and 20/50, or worse, vision.
Caring for patients in ourand offices, Dr. Abbey also serves as our Director of Clinical Research for Dallas. You can learn more about him .